MTX vs UAMY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MTX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MTX and UAMY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MTX and UAMY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Minerals Technologies Inc. (NYSE: MTX) is a global specialty minerals company built originally out of Pfizer's minerals unit. It is one of the largest producers of precipitated calcium carbonate (PCC) and the world's largest bentonite producer, and it organizes its business into two segments: Consumer & Specialties (household and personal care products such as cat litter, personal care, fabric care, edible-oil purification, plus specialty additives) at roughly 53% of sales, and Engineered Solutions (high-temperature refractory technologies and environmental and infrastructure products) at roughly 47%. The company sells into paper, packaging, construction, automotive, foundry, steel, and consumer markets across more than 35 countries.

Full MTX guide

United States Antimony Corporation (NYSE: UAMY, also listed on NYSE Texas) has been processing antimony in Montana since 1970 and moved from NYSE American to the New York Stock Exchange in March 2026. It reports two segments. The antimony segment covers the Thompson Falls smelter in Sanders County, Montana, which turns ore into antimony oxide, metal ingots, trisulfide and a small stream of gold and silver, plus the Madero smelter in Mexico run through its USAMSA subsidiary. The zeolite segment is Bear River Zeolite in Preston, Idaho, which surface mines and sells zeolite for water filtration, soil amendment and animal feed. Around those two segments sits a widening set of early-stage assets: the restarted Stibnite Hill mine and the new Radersburg flotation mill in Montana, claims at Nolan Creek and in the Fairbanks District of Alaska, the Fostung tungsten project in Ontario, and a hydrometallurgical joint venture with Americas Gold and Silver in Idaho. The company employed ~100 full-time staff at the end of 2025.

Full UAMY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MTX drivers: Diversified specialty-minerals franchise; Return to growth and margin recovery.
• UAMY drivers: The tripled Montana smelter; Government demand as a floor.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the talc litigation itself: the reorganization plan must be confirmed and funded, and a large charge (around $290 million booked in 2026) already pressures reported results, with the possibility of adverse rulings or higher-than-expected claim funding. For UAMY, the antimony price cycle dominates everything.

Pick MTX if you believe its drivers more; UAMY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MTX and UAMY guides.

MTX. MTX trades at roughly 14 times earnings, a discount to the broader chemicals and materials group, which reflects the market pricing in talc-litigation uncertainty rather than weak operations. Revenue of about $2.1 billion generates operating income in the low-double-digit-percent margin range, and Q1 2026 showed both revenue growth and a profit rebound. The valuation gap is the crux of the debate: bulls see a discount that narrows once the litigation is capped, while the reported figures remain distorted by large one-time reserve charges.

UAMY. The valuation rests on capacity and contracts rather than current output. Full-year 2025 revenue of ~$39.3M was itself inflated by peak antimony pricing, and the first half of 2026 came in at ~$14.7M against ~$17.5M a year earlier. Management authorized a ~$100M share repurchase on 19 August 2026, saying the board considered the stock undervalued, four months after raising ~$49.1M of equity.

Headline figures (approximate, JULY 2026): MTX shows revenue (ttm) ~$2.1B, market cap ~$1.8B, p/e ratio ~14x, q1 2026 revenue ~$547M (up ~11% YoY); UAMY shows revenue (ttm) ~$36.4M, q2 2026 revenue ~$7.9M, down from ~$10.5M, q2 2026 gross margin ~7%, down from ~27%, net loss (ttm) ~$16.3M.

MTX and UAMY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MTX and UAMY exposure against your real portfolio. It is not an investment adviser.